Skip to content
HeyJared

Howard Sklamberg

Reporter · US

Indexed articles, last 90 days
3
Latest publication
Sep 18, 2026
Outlet visibility, for Mondaq
Top 500K sites
Earliest in this view
Jul 14, 2026

Latest articles

  1. Article · Sep 18, 2026 · Howard Sklamberg

    Root Causes: Updates And Insights On Quality And Inspections (opens the original)

    Excerpt · English

    Read excerpt

    We are happy to launch a new newsletter, Root Causes: Updates and Insights on Quality and Inspections. The newsletter, which will come out roughly monthly, will discuss new developments in FDA inspections and enforcement, and its regulation of manufacturing and clinical trials. We will also discuss occasional developments from overseas regulators, such as in Europe, that affect the U.S. market. Manufacturing and chemistry, manufacturing, and controls (CMC) issues remain at the center of the U.S.

  2. Article · Aug 13, 2026 · Howard Sklamberg

    FDA Proposes Mandatory GRAS Notification Requirement (opens the original)

    Excerpt · Neutral tone · English

    Read excerpt

    On August 11, 2026, the U.S. Food and Drug Administration (FDA) published a proposed rule that would convert the currently voluntary Generally Recognized as Safe (GRAS) notification program into a mandatory requirement. If finalized, any person who introduces a substance into interstate commerce based on self-determined GRAS status would be required to notify FDA of the GRAS determination and provide supporting documentation. The notification requirement would apply to products currently on the

  3. Article · Jul 14, 2026 · Howard Sklamberg

    FDA Proposes New Registration And Listing Pathway For Distributed Drug Manufacturing And Aligns Foreign Establishment Obligations With Current Law (opens the original)

    Excerpt · English

    Read excerpt

    On July 13, 2026, the U.S. Food and Drug Administration (FDA) published a proposed rule that would amend the drug establishment registration and drug listing requirements for establishments engaged in distributed manufacturing (DM) and for foreign drug establishments.1 First, it would create a DM-specific registration pathway for distributed manufacturing establishments (DMEs) that meet select criteria. Second, it proposes updates to the drug establishment registration and drug listing requireme

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 500K sites

For Mondaq, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Howard Sklamberg